The Trump administration is planning to ramp up oversight and enforcement of direct-to-consumer prescription drug advertising, but will stop short of an outright ban.

President Trump on Tuesday signed an executive memorandum instructing the Department of Health and Human Services to ensure transparency and accuracy in direct-to-consumer advertising, including by requiring greater disclosures of side effects.

The Food and Drug Administration sent out approximately 100 cease-and-desist enforcement letters, as well as thousands of warning letters to inform companies the agency is prioritizing enforcement.

The announcement follows up on the administration’s Make America Healthy Again........

© The Hill